J.P. Morgan week and WuXi Global Forum 2025 in San Francisco
13-16 January, 2025
San Francisco, CA, USA
ENYO Pharma will in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
ENYO Pharma will also take the opportunity to host an executive roundtable at WuXi-Global-Forum-2025 on the 14th of January to share our progress in drug development with Vonafexor in kidney diseases.
4th Rare & Genetic Kidney Disease Drug Development Summit
10-12 December 2024
Boston, MA, USA
ENYO Pharma will attend for the first time the 4th Rare & Genetic Kidney Disease Drug Development Summit that will be held in Boston, USA. The event will bring together industries, academic KOLs, and patient advocacy nephrology communities to discuss acceleration of clinical advancements in orphan kidney disease populations.
ENYO Pharma will present the ongoing ALPESTRIA-1 Phase 2 clinical trial with Vonafexor in patients with Alport syndrome.
MOSAIC – the Global NASH/MASH Trialist Forum
24-25 October 2024
Washington DC, USA
ENYO Pharma is attending the MOSAIC – Global NASH Trialist Forum 2024. The goal of the meeting was to define new integrative Cardiovascular-Kidney-Liver-Metabolic (CKLM) trials together with cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders.
FEDERG meeting – Federation of European Patient Groups affected by Rare/Genetic Kidney Diseases
14 September 2024
Martorell, Spain
The Federation of European Patient Groups affected by Rare/Genetic Kidney Diseases, FEDERG, was organising its “fighting for our federation Federg f2f Members” meeting on the 14th of September in Martorell in Spain. The objective of the meeting was to plan new practical actions that help improve and promote knowledge of these pathologies, promote research, and be an active part in the political decision-making process for the inclusion of our pathologies.
The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
The first patient with Alport Syndrome received their first oral doses of Vonafexor last month in the US as part of our Phase 2 ALPESTRIA-1 clinical study.
ALPESTRIA-1 evaluates the safety and the effects of Vonafexor on kidney function in subjects with at risk of progression Alport syndrome. The total duration of study for a participant will be up to 40 weeks and include a screening period, a treatment period of 24 weeks and a follow-up period of 12 weeks.
Latest Press Release 